This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boyd, D. D. Articles by Gallick, G. E. Search for Related Content PubMed PubMed Citation Articles by Boyd, D. D. Articles by Gallick, G. E.

(American Journal of Pathology. 2003;162:619-626.)
© 2003 American Society for Investigative Pathology

Regular Articles

A Urokinase-Derived Peptide (Å6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis

Douglas D. Boyd^*, Sun-Jin Kim^*, Heng Wang^*, Terence R. Jones and Gary E. Gallick^*

From the Department of Cancer Biology,^* M.D. Anderson Cancer Center, Houston, Texas; and Ångstrom Pharmaceuticals Inc., San Diego, California

The high rate of prostate cancer mortality invariably reflects the inability to control the spread of the disease. The urokinase-type plasminogen activator and its receptor (u-PAR) contribute to prostate cancer metastases by promoting extracellular matrix degradation and growth factor activation. The current study was undertaken to determine the efficacy of a urokinase-derived peptide (Å6) in reducing the lymph node metastases of prostate cancer using a model in which prostatic tumors established in nude mice from orthotopically implanted PC-3 LN4 prostate cancer cells disseminate to the lymph nodes. As a first step in evaluating the in vivo effectiveness of Å6, we determined its effect on in vitro invasiveness. In vitro, Å6 reduced the invasiveness of PC-3 LN4 cells through a Matrigel-coated filter without affecting growth rate. A first in vivo survival experiment showed that all Å6-treated mice were alive after 57 days, and half of them tumor-free, whereas all control mice receiving vehicle had died. In a second experiment with a larger tumor inoculum and a longer delay until treatment, whereas 71% of control mice and 83% of mice treated with a scrambled peptide developed lymph node metastases, only 22 to 25% of Å6-treated mice had positive lymph nodes. Further, lymph node volume, reflective of tumor burden at the secondary site, was diminished 70% in Å6-treated mice. In conclusion, we provide definitive evidence that a peptide spanning the connecting region of urokinase suppresses metastases and, as a single modality, prolongs the life span of prostate tumor-bearing mice.

This article has been cited by other articles:

				Y. Wang, P. Nangia-Makker, L. Tait, V. Balan, V. Hogan, K. J. Pienta, and A. Raz Regulation of Prostate Cancer Progression by Galectin-3 Am. J. Pathol., April 1, 2009; 174(4): 1515 - 1523. [Abstract] [Full Text] [PDF]

				S. M. Pulukuri, C. S. Gondi, S. S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J. S. Rao RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo J. Biol. Chem., October 28, 2005; 280(43): 36529 - 36540. [Abstract] [Full Text] [PDF]

				H. J. Koh, K. Bessho, L. Cheng, D.-U. Bartsch, T. R. Jones, G. Bergeron-Lynn, and W. R. Freeman Inhibition of Choroidal Neovascularization in Rats by the Urokinase-Derived Peptide A6 Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 635 - 640. [Abstract] [Full Text] [PDF]

				J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]

				P. G. McGuire, T. R. Jones, N. Talarico, E. Warren, and A. Das The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2736 - 2742. [Abstract] [Full Text] [PDF]